TITLE

Don't want a $1 million fine? Pay attention to regulated drugs

PUB. DATE
December 2011
SOURCE
Same-Day Surgery;Dec2011, Vol. 35 Issue 12, p125
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the case of a hospital-affiliated clinic and surgery center in Oklahoma that was fined $1 million in a settlement over claims that they failed to comply with federal regulations regarding record-keeping and inventory of regulated drugs.
ACCESSION #
67649572

 

Related Articles

  • Daily counts help avoid diversion.  // Same-Day Surgery;Dec2011, Vol. 35 Issue 12, p127 

    The article reports on an announcement from Sheldon S. Sones, president of Sheldon S. Sones and Associates, a medication and pharmacy consulting firm, in which Sones indicated that daily counts of regulated drugs are one step to ensure compliance and to avoid diversion in health facilities.

  • Ensure these steps for controlled substances. Dembny, Christopher M. // Same-Day Surgery;Dec2011, Vol. 35 Issue 12, p130 

    The article reports on methods which health care facilities can use to track and administer controlled drugs and to avoid the diversion of the drugs. INSET: Potentials Signs of Diversion.

  • Tips and Questions for Good Operating Procedures. Jones, David E. // Journal of GXP Compliance;May2013, Vol. 17 Issue 2, p1 

    The article presents tips and questions for those who want improvement in their good operating procedures on topics, that include adequacy of procedure, avoidance of information duplication, and inclusion of who, what, and when in steps. The author explains that in adequacy of procedure,...

  • Still in the dark. Daly, Rich // Modern Healthcare;3/12/2012, Vol. 42 Issue 11, p36 

    The article discusses the implication of the Physical Payments Sunshine Act for the U.S. healthcare industry in 2012. Under the law, the Centers for Medicare and Medicaid Services (CMS) will be required to annually publish online the payments made to physicians. It mentions the failure of...

  • FDA grants four-month delay for some track-and-trace provisions. Traynor, Kate // American Journal of Health-System Pharmacy;8/15/2015, Vol. 72 Issue 16, p1339 

    The article reports on the extension for the track-and-trace requirement under the Drug Supply Chain Security Act until November 1, 2015 by the U.S. federal agency Food and Drug Administration. Topics covered include the receipt, storage, and retrieval of product information that may be used for...

  • ICD-10 Forcing Providers to Reassess HIM Strategy.  // For the Record (Great Valley Publishing Company, Inc.);2/11/2013, Vol. 25 Issue 3, p27 

    The article reports that KLAS, healthcare provider is analyzing their health information management (HIM) strategies with International Classification of Disease (ICD)-10 to overcome the challenges related to organizational expansion and consolidation in the U.S. It mentions that health provider...

  • Preparation, Preparation, and More Preparation. Graham, Ballard; Poska, Richard; Ertmann, Robert; Pluta, Paul L. // Journal of GXP Compliance;Autumn2011, Vol. 15 Issue 4, p14 

    The article discusses guidelines for preparing for compliance audits in the U.S. pharmaceutical industry. Audit personnel which must be identified are mentioned including the primary audit contact, and audit coordinator. Activities required for audits are explained such as site visit policy,...

  • Structured GMP Audits. Brandt, Carol // Journal of GXP Compliance;Aug2014, Vol. 18 Issue 3, p1 

    Although Good Manufacturing Practices (GMP) audits are common both for internal and external customers, a structured approach to planning and execution can result in a successful well executed audit. There are a variety of audit types (GMP baseline, GMP risk-based, due diligence,...

  • FDA Approval Boosts Santarus Stock Price. Chambers, Heather // San Diego Business Journal;12/7/2009, Vol. 30 Issue 49, p5 

    The article discusses the effect on the share price of the company stock of Santarus Inc. of San Diego, California, after it received U.S. Food & Drug Administration (FDA) approval for its over-the-counter version of the heartburn drug Zegerid. The drug is a combination of omeprazole and an antacid.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics